HRA002200
Title:
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with a highly selective inhibitor for the treatment of prostate cancer
Release date:
2022-04-07
Description:
Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide, and hormonal therapy plays a key role in the treatment of PCa. However, the inevitable drug resistance of hormonal therapy makes it urgent and necessary to identify novel targets for PCa treatment. Herein, dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) was found and confirmed to be highly expressed in the PCa tissues and cells, and knock-down of DYRK2 remarkably reduced PCa burden in vitro and in vivo. On the base of DYRK2 acting as a promising target, we further discovered a highly selective DYRK2 inhibitor YK-2-69, which specifically interacted with Lys-231 and Lys-234 in the co-crystal structure. Especially, YK-2-69 exhibited more potent anti-PCa efficacy than the first-line drug enzalutamide in vivo. Meanwhile, YK-2-69 displayed excellent safety properties with a maximal tolerable dose of more than 10,000 mg/kg and great pharmacokinetic profiles with 56% bioavailability.
Data Accessibility:   
Open access
BioProject:
Study type:
Cell line related study
Disease name:
Prostate cancer
Dataset Download
MetaData:
Files:
Aspera Command Line:  Help   

 Note: HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client) or Asepra Command Line.

Individuals & samples
Files
Submitter:   Yang Peng / pengyang@cpu.edu.cn
Organization:   China Pharmaceutical University
Submission date:   2022-03-31